Operating in stealth since 2021, Synnovation Therapeutics introduced itself on 24 January by announcing a $102m series A financing that it said should provide capital adequate to last into 2026 and get its first three candidates into the clinic. The Wilmington, DE-based firm will start out with a focus on precision therapy for cancer and an executive suite composed mainly of former Incyte Corporation scientists.
Synnovation Aims At Precision Oncology With $102m In Venture Backing
Third Rock Ventures is leading a $102m series A for Synnovation, a cancer-focused biotech led by several former Incyte scientists. The new firm wants to develop best-in-class drugs against validated targets.
